This article may contain affiliate links. We may earn a commission if you purchase through these links, at no extra cost to you.

GLP-1 Medication Costs in 2026: Prices, Insurance, Medicare, and How to Save

If you have been researching GLP-1 medications for weight loss or diabetes, the first question on your mind is probably: How much is this actually going to cost me?

The honest answer is that it depends. GLP-1 prices in 2026 range from as low as $25 per month with the right insurance and savings card to over $1,300 per month at full list price. The gap between those two numbers is enormous, and navigating it can feel overwhelming.

The good news is that 2026 has brought more savings options than ever before. New government programs, manufacturer price cuts, oral formulations, and direct-to-consumer platforms have created real pathways to affordable treatment. Medicare coverage is arriving for the first time ever. The oral Wegovy pill launched at a fraction of the injectable price. And manufacturers are competing to offer the most aggressive self-pay discounts.

This guide breaks down every option so you can find the one that works for your budget. We cover brand-name prices, insurance strategies, Medicare expansion, manufacturer savings programs, telehealth platforms, compounding pharmacy options, and a step-by-step decision tree to find your lowest possible cost.

Quick Answer

Brand-name GLP-1 list prices remain high — Wegovy costs about $1,349/month and Ozempic about $997/month at full retail — but almost nobody should be paying list price in 2026 thanks to savings cards, self-pay programs, and new government initiatives.
TrumpRx and manufacturer self-pay programs have dropped cash prices significantly — injectable Wegovy and Ozempic start at $199/month for low doses, Zepbound starts at $299/month through LillyDirect, and the new oral Wegovy pill starts at $149/month.
Medicare GLP-1 coverage begins July 2026 — the Medicare GLP-1 Bridge program will offer eligible beneficiaries GLP-1 medications for $50/month, covering an estimated 10% of Medicare enrollees in Phase 1.
With commercial insurance and a manufacturer savings card, most patients pay $25/month for Wegovy, Ozempic, or Zepbound — but prior authorization approval rates average only 60-70%, so documentation matters.

Brand-Name GLP-1 Prices at a Glance

Before we dig into savings strategies, here is what each major GLP-1 medication costs at full retail price in 2026. These are the numbers you will see without insurance or any discount program.

Semaglutide Medications (Novo Nordisk)

Wegovy (injectable): approximately $1,349 per 28-day supply
Ozempic (injectable): approximately $997 per month
Oral Wegovy (pill): $149 to $299 per month depending on dose (new self-pay pricing from Novo Nordisk)

The oral Wegovy pill, which became broadly available across 70,000+ U.S. pharmacies in early 2026, represents a major shift. At $149/month for the 1.5 mg starting dose and $299/month for the highest doses (9 mg and 25 mg), it is dramatically cheaper than the injectable for self-pay patients.

Tirzepatide Medications (Eli Lilly)

Mounjaro (injectable, for diabetes): approximately $1,086 per month
Zepbound (injectable, for weight loss): approximately $1,086 per month
Zepbound single-dose vial: $449 per month for maintenance doses (7.5-15 mg)

Eli Lilly introduced the Zepbound single-dose vial in late 2025 specifically to offer a lower self-pay price point, and expanded availability of the KwikPen for single-patient use at $449/month starting February 2026.

Price Comparison Table

Medication	Monthly List Price	Best Self-Pay Price	With Insurance + Savings Card
Wegovy (injectable)	$1,349	$199-$349	As low as $25
Ozempic (injectable)	$997	$199-$499	As low as $25
Oral Wegovy (pill)	$149-$299	$149-$299	As low as $25
Zepbound (injectable)	$1,086	$299-$449	As low as $25
Mounjaro (injectable)	$1,086	$299-$449	As low as $25

For a deeper look at how these medications compare beyond price, see our guide to the best GLP-1 medications for weight loss in 2026.

TrumpRx: The New Government Savings Platform

One of the biggest developments of 2026 is TrumpRx.gov, which launched on February 5, 2026 as part of the administration's Most Favored Nation (MFN) pricing initiative. The platform negotiated directly with Novo Nordisk and Eli Lilly to bring GLP-1 prices down for consumers who pay out of pocket.

TrumpRx GLP-1 Prices

Oral Wegovy pill: as low as $149/month
Injectable Wegovy and Ozempic: average of $350/month, as low as $199 depending on dose
Zepbound: average of $346/month, starting at $299

What You Need to Know

TrumpRx is not a pharmacy or insurance plan. It is a portal that directs you to manufacturer websites (NovoCare and LillyDirect) where you purchase at the negotiated price. There are important limitations:

Purchases do not count toward your insurance deductible or out-of-pocket maximum. If you have insurance that might cover GLP-1s, check that route first.
No clinical support is included. You still need a prescriber, lab work, and ongoing monitoring from your own doctor or a telehealth provider.
You need a valid prescription. The platform connects you to the medication, not to a care team.

For many uninsured or underinsured Americans, TrumpRx represents real savings of 60-75% compared to retail pharmacy prices. But it is not the cheapest option for everyone. Read on for other pathways.

Insurance Coverage: What Is and Is Not Covered

Insurance coverage for GLP-1 medications in 2026 is a patchwork. Your experience depends heavily on your specific plan, your diagnosis, and how persistent you are with paperwork. Two people living on the same street with different employers can face wildly different costs for the same medication. Understanding the landscape helps you know where you stand and what to fight for.

Commercial (Employer) Insurance

About 40-50% of commercial health plans now cover GLP-1 medications for weight loss with prior authorization. Coverage rates are significantly higher for diabetes indications — most plans cover Ozempic and Mounjaro for Type 2 diabetes management, even if they exclude weight loss indications like Wegovy and Zepbound.

The distinction matters. If you have both obesity and prediabetes or Type 2 diabetes, your doctor may be able to prescribe a covered diabetes medication (like Ozempic or Mounjaro) that also produces weight loss, even if your plan does not cover medications specifically approved for obesity.

Prior authorization approval rates average 60-70% when complete documentation is provided. Here is what most insurers require:

Two BMI measurements taken at different visits
Documentation of comorbidities (sleep apnea, hypertension, high cholesterol, etc.)
Proof of 3-6 months of diet and exercise failure (sometimes called "lifestyle modification documentation")
Lab work showing relevant health markers
A letter of medical necessity from your prescribing doctor

Tips to improve your chances:

Ask your doctor's office if they have experience with GLP-1 prior authorizations. Some offices have staff dedicated to this process. Practices that regularly prescribe GLP-1s know exactly what documentation each major insurer requires and can often get approvals faster.
Start documenting your weight management efforts now. Keep records of diet programs, gym memberships, nutritionist visits, or calorie-tracking apps. Many insurers require 3-6 months of documented "lifestyle modification failure" before they will approve a GLP-1. If you have not been formally tracking your efforts, start today.
If denied, appeal. First-round denials are common, and many are overturned on appeal with additional documentation. Ask your doctor to write a detailed letter of medical necessity citing your specific health risks. Include any published clinical trial data showing that the medication reduces cardiovascular events or other serious outcomes relevant to your conditions.
Ask about alternative covered indications. Wegovy received expanded FDA approval for cardiovascular risk reduction. If your plan denies it for weight loss but covers it for cardiovascular indications, your doctor may be able to submit under a different diagnosis code.
Check your plan's step therapy requirements. Some insurers require you to try (and fail) a cheaper medication first, like phentermine or naltrexone-bupropion, before they will approve a GLP-1. Knowing this upfront saves time.

State Medicaid Programs

Medicaid coverage for GLP-1 weight loss medications has actually contracted in some states. As of early 2026, only 13 states cover GLP-1 medications for weight loss through Medicaid, down from 16 after California, Pennsylvania, and Michigan eliminated coverage on January 1, 2026.

California's Medi-Cal, for example, discontinued coverage of GLP-1s prescribed solely for weight loss in adults. Some medications may still be covered for non-weight-loss indications (like Type 2 diabetes) through prior authorization.

If you are on Medicaid, contact your state program directly to check current coverage. The CMS BALANCE Model, launching in Medicaid as early as May 2026, may expand access in participating states.

Medicare GLP-1 Coverage: What Changes in 2026

This is the section many readers have been waiting for. For years, Medicare was legally prohibited from covering anti-obesity medications. That is finally changing in 2026.

Medicare GLP-1 Bridge Program (July 2026)

CMS is launching a Medicare GLP-1 payment demonstration starting July 1, 2026, running through December 31, 2026. This "bridge" program will serve as a short-term path while the longer-term BALANCE Model is developed.

Key details:

Eligible Medicare beneficiaries will pay $50 per month for GLP-1 medications
Your medical provider must submit a prior authorization request and a prescription
The program operates outside of the standard Medicare Part D benefit, meaning Part D plan sponsors do not carry the cost
CMS will release additional prior authorization details in Spring 2026

Who Is Eligible?

Phase 1 eligibility includes:

Overweight individuals with a BMI greater than 27 plus prediabetes or diagnosed cardiovascular disease
This is estimated to cover about 10% of Medicare beneficiaries

Phase 2 (expected to expand later) will include:

Individuals with a BMI greater than 30
Individuals with uncontrolled hypertension, kidney disease, or heart failure

BALANCE Model (2027 and Beyond)

The BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) Model will launch in Medicare Part D in January 2027. Under this voluntary model, CMS will negotiate drug pricing and coverage terms directly with GLP-1 manufacturers on behalf of Part D plan sponsors.

If you are on Medicare: Mark your calendar for July 2026. Talk to your doctor now about whether you might qualify for the bridge program, and make sure your medical records document your BMI history and any qualifying conditions.

Manufacturer Savings Programs and Coupon Cards

Both Novo Nordisk and Eli Lilly offer savings programs that can dramatically reduce your costs. These are often the single best way to lower your out-of-pocket expense.

Wegovy Savings Card (Novo Nordisk)

With commercial insurance: Pay as little as $25 per month, with up to $500/month in savings
Self-pay introductory offer: $199/month for starter doses (0.25 mg and 0.5 mg) for your first 2 fills through March 31, 2026
Self-pay after introductory period: $349/month for lower doses, $499/month for maintenance doses
How to activate: Visit wegovy.com/savings or text "SAVE" to 83757
Not eligible: Medicare, Medicaid, and other government insurance beneficiaries

Ozempic Savings Card (Novo Nordisk)

With commercial insurance: Pay as little as $25 per fill for up to a 3-month prescription
Self-pay introductory offer: $199/month for 0.25 mg and 0.5 mg doses (through March 31, 2026)
Self-pay after introductory period: $349/month for doses up to 1 mg, $499/month for 2 mg
How to activate: Visit ozempic.com/savings or call 1-888-793-1218

Zepbound Savings Card (Eli Lilly)

With commercial insurance: Pay as little as $25 per fill, with maximum monthly savings of $100 per 1-month supply (up to $1,300 per year)
LillyDirect self-pay: $299/month for the 2.5 mg starting dose, $449/month for all higher doses
Card expires: December 31, 2026
How to activate: Visit zepbound.lilly.com/savings

Costco and Walmart Programs

Retail giants have also entered the GLP-1 savings space:

Costco: Sells Wegovy and Ozempic for $499/month for cash-pay customers (no Costco membership required for pharmacy purchases in most states)
Walmart: Offers a comparable arrangement with Eli Lilly for Zepbound

GoodRx Coupons

GoodRx offers an introductory price for the first two fills: $199 per month for Ozempic or Wegovy injections, or $149 for the Wegovy pill. After the introductory period, GoodRx prices will match manufacturer self-pay pricing.

Oral Wegovy: The Game-Changer for Cost

The launch of oral Wegovy (semaglutide pills) in early 2026 is arguably the most significant cost development this year. For the first time, patients can take a daily GLP-1 pill instead of a weekly injection, and the pricing structure is fundamentally different.

Oral Wegovy Pricing Breakdown

Dose	Monthly Price	Notes
1.5 mg (starting)	$149	Introductory dose
4 mg	$149 until April 15, then $199	Transitional pricing
9 mg	$299	Maintenance dose
25 mg	$299	Highest dose

Why the Pill Is Cheaper

The oral formulation does not require the cold-chain storage and specialized injection devices of the injectable version. Manufacturing and distribution costs are lower, and Novo Nordisk has priced it aggressively to compete with compounding pharmacies and drive broader adoption.

For a detailed comparison of the pill versus the injection, including effectiveness data, see our guide on Wegovy pill vs. Wegovy injection.

Compounded Semaglutide: Cheaper, but Changing Fast

Compounded semaglutide has been the go-to option for budget-conscious patients, typically costing $149 to $299 per month compared to $997+ for brand-name Ozempic. That is a savings of 70-80%. But the landscape shifted significantly in early 2026.

What Changed

When the FDA ended the semaglutide shortage in February 2026, it also tightened regulations around compounding. During the shortage, the Federal Food, Drug, and Cosmetic Act allowed compounding pharmacies broader latitude to produce copies of drugs that were in short supply. Once the shortage was resolved, that exception narrowed significantly.

Compounding pharmacies can now only provide semaglutide for patients with documented medical needs, such as:

Allergies to inactive ingredients in the brand-name product (such as specific preservatives or stabilizers)
Need for specific dosing not available commercially (pediatric doses, unusual titration schedules)
Intolerance to the delivery mechanism (patients who cannot use auto-injectors or standard pen devices)
Other clinically justified reasons documented by a prescriber

This means the days of easily ordering compounded semaglutide online without a specific medical justification are largely over. Many telehealth platforms that previously built their business on compounded semaglutide have pivoted to partnerships with Novo Nordisk and Eli Lilly to offer brand-name products instead.

Is Compounded Semaglutide Still Available?

Yes, but through fewer providers and with more requirements. Prices from remaining reputable providers range from $159 to $299 per month. If you are considering this route, our guide on whether compounded semaglutide is safe and legal in 2026 covers everything you need to know, including how to verify your pharmacy is legitimate.

Compounded vs. Brand-Name: Key Differences

Factor	Compounded Semaglutide	Brand-Name (Ozempic/Wegovy)
Monthly cost	$159-$299	$997-$1,349 (list)
FDA approved	No	Yes
Manufacturing oversight	State pharmacy boards	FDA-regulated
Insurance accepted	Rarely	Yes, with prior auth
Availability in 2026	Restricted	Widely available

Telehealth Platform Pricing

Online weight loss clinics have become one of the most popular ways to access GLP-1 medications, combining prescriber visits, medication, and ongoing support into monthly programs. For many patients, these platforms eliminate the need for multiple in-person doctor visits and simplify the entire process into a single monthly cost. Here is what the major platforms charge in 2026.

Hims & Hers

Hims & Hers recently partnered directly with Novo Nordisk to offer FDA-approved GLP-1 medications (Ozempic and Wegovy in both injectable and pill forms). Earlier in 2026, Hims briefly offered a compounded Wegovy pill for $49/month before regulatory and legal pressure from Novo Nordisk shut down that effort within days.

Current pricing aligns with Novo Nordisk's self-pay rates, plus a platform consultation fee. The Hims platform includes an initial provider consultation, ongoing messaging access with your prescriber, and dose adjustment support.

Ro

Ro's weight management program offers transparent, tiered pricing:

Ro Body membership: $45 for the first month, then $145/month (includes provider access, regular check-ins, metabolic health tracking, and clinical support)
Wegovy pill through Ro: $149/month for 1.5 mg and 4 mg doses (4 mg price valid through April 15, 2026, then $199), $299/month for 9 mg and 25 mg doses
Medication cost is separate from the membership fee

Ro's strength is in its structured clinical program. The membership includes regular metabolic lab monitoring, body composition tracking, and access to dietitian-developed meal plans. For patients who want a comprehensive medical weight management program rather than just a prescription, this added structure may justify the membership fee.

Other Platforms

Several other telehealth platforms offer GLP-1 programs, including LifeMD, Weight Watchers, and Found. Pricing varies but generally falls between $149 and $399/month for medication plus a consultation or membership fee of $50 to $199/month.

When comparing platforms, look beyond the headline price. Consider what is included in the membership fee — some platforms offer dietitian access, exercise guidance, and community support, while others are essentially a prescriber visit and nothing more. The cheapest platform is not always the best value if it leaves you without the clinical support you need to use the medication safely and effectively.

For a detailed comparison of the top online programs, including what is included beyond just the medication, check out our rankings of the best online GLP-1 programs in 2026 and our head-to-head comparison of Hims vs. Ro vs. Found for weight loss.

How to Get the Lowest Possible Price: A Step-by-Step Guide

With so many options available, here is a practical decision tree to find your lowest cost path.

Step 1: Check Your Insurance

Call the number on the back of your insurance card and ask:

"Does my plan cover Wegovy, Ozempic, Zepbound, or Mounjaro?"
"What is the prior authorization process?"
"What tier is the medication on your formulary?"

If your plan covers a GLP-1, your cost with a manufacturer savings card could be as low as $25/month. This is almost always the cheapest option.

Step 2: If Insured but Not Covered

Ask your doctor about appealing or switching to a covered medication
Check if your plan covers the medication for a different indication (diabetes vs. weight loss)
Consider the oral Wegovy pill, which some plans cover differently than the injectable

Step 3: If Uninsured or Self-Pay

Compare these options from cheapest to most expensive:

Oral Wegovy pill: $149-$299/month depending on dose
Zepbound through LillyDirect: $299-$449/month
TrumpRx prices: Ozempic/Wegovy injectable at $199-$350/month
Manufacturer self-pay programs: Ozempic/Wegovy at $199-$499/month
Costco/Walmart: $499/month for Wegovy/Ozempic or Zepbound

Step 4: If on Medicare

Before July 2026: Check if you qualify for any state pharmaceutical assistance programs. Ask your doctor about off-label use of covered diabetes medications if you have prediabetes or Type 2 diabetes.
After July 2026: Ask your provider about the Medicare GLP-1 Bridge program ($50/month for eligible beneficiaries).

Step 5: If on Medicaid

Check your state's current formulary. Only 13 states cover GLP-1s for weight loss as of early 2026.
The BALANCE Model may expand Medicaid access starting May 2026 in participating states.
GLP-1s prescribed for Type 2 diabetes have broader Medicaid coverage than those prescribed for weight loss.

If you need help finding a prescriber, our guide on how to get a GLP-1 prescription online walks through the process.

Hidden Costs to Watch For

The sticker price of the medication is not the only expense. Budget for these additional costs:

Provider Visits

In-person doctor visits: $150-$300 per visit (typically quarterly)
Telehealth consultations: $50-$199/month depending on the platform
Lab work: $100-$300 for initial labs, $50-$150 for follow-ups (check if your insurance covers preventive labs)

Supplies and Side Effect Management

Needles and syringes (injectable GLP-1s): Usually included with the medication
Alcohol swabs and sharps container: $10-$20
Anti-nausea medication (for side effects): $10-$30/month if needed
Protein supplements (to prevent muscle loss): $30-$60/month recommended

Long-Term Considerations

GLP-1 medications are typically used long-term. Research from the STEP 1 trial extension (2023) showed that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. This means budgeting for GLP-1 medication is more like budgeting for a chronic condition treatment than a one-time expense.

Factor the ongoing monthly cost into your budget as a recurring expense. At the most affordable self-pay price point ($149/month for oral Wegovy starting dose), that is $1,788 per year. At higher doses or through injectable formulations, annual costs can reach $3,588 to $5,400 even with self-pay discounts.

Some patients work with their doctors to find a maintenance dose that is lower (and cheaper) than their weight loss dose. Others explore cycling strategies or transitioning to lifestyle-only maintenance after reaching their goal weight. Discuss long-term planning with your provider early so you are not caught off guard by ongoing costs.

What Is Coming: Price Trends to Watch in Late 2026 and Beyond

The GLP-1 pricing landscape is evolving faster than almost any drug category in history. Several developments could further reduce costs in the coming months and years:

Medicare BALANCE Model (January 2027): Full Medicare Part D negotiated pricing for GLP-1s, potentially reaching more beneficiaries than the bridge program
TrumpRx price reductions: The administration has stated that average GLP-1 prices on TrumpRx will trend down to $245/month over the next two years
Generic competition: While no generic semaglutide or tirzepatide is expected before 2031-2032, increasing competition among branded products is already driving prices down
Additional oral formulations: Eli Lilly's oral tirzepatide (orforglipron) is in late-stage trials, which could add more competition in the affordable pill category
Employer plan coverage expansion: As evidence mounts that GLP-1s reduce cardiovascular events and total healthcare spending, more employer plans are expected to add coverage. A 2024 J.P. Morgan analysis estimated that GLP-1s could reduce total healthcare costs by $4,000-$7,000 per patient per year when accounting for fewer hospitalizations, reduced diabetes medications, and lower cardiovascular event rates. This data is making the business case for coverage increasingly compelling to self-insured employers.
International price benchmarking: GLP-1 medications cost significantly less in other countries — Ozempic costs approximately $150-$300/month in Canada and parts of Europe. The TrumpRx Most Favored Nation pricing framework is designed to bring U.S. prices closer to international benchmarks over time

Frequently Asked Questions

Q: What is the cheapest way to get a GLP-1 medication in 2026?

The cheapest option depends on your insurance status. If you have commercial insurance that covers a GLP-1, using the manufacturer savings card brings your cost to as low as $25/month — this is almost always the least expensive route. For self-pay patients without insurance coverage, the oral Wegovy pill at $149/month for the starting dose is currently the lowest-cost FDA-approved option. Medicare beneficiaries who qualify for the GLP-1 Bridge program starting July 2026 will pay $50/month. Compounded semaglutide, where still available under the new restrictions, ranges from $159-$299/month. The key is to explore all options before settling on a price — many patients pay far more than they need to simply because they did not know about manufacturer savings programs or self-pay pricing tiers.

Q: Does Medicare cover Ozempic or Wegovy for weight loss in 2026?

Medicare Part D has covered Ozempic for Type 2 diabetes for several years. Coverage for weight loss specifically begins with the Medicare GLP-1 Bridge program on July 1, 2026, where eligible beneficiaries will pay $50/month. Eligibility in Phase 1 requires a BMI over 27 plus prediabetes or cardiovascular disease. The broader BALANCE Model expands to Medicare Part D in January 2027.

Q: Is compounded semaglutide still available and legal in 2026?

Compounded semaglutide is still available but under tighter restrictions. After the FDA ended the semaglutide shortage in February 2026, compounding pharmacies can only provide it for patients with documented medical needs, such as allergies to brand-name ingredients or specific dosing requirements. Prices from legitimate providers range from $159 to $299/month. Always verify that your compounding pharmacy is licensed and follows FDA guidelines.

Q: Can I use a GLP-1 savings card if I have Medicare or Medicaid?

No. Federal law prohibits manufacturer savings cards and coupons for patients with government-funded insurance, including Medicare, Medicaid, Tricare, and VA benefits. However, the Medicare GLP-1 Bridge program ($50/month starting July 2026) and the Medicaid BALANCE Model (starting as early as May 2026) offer alternative savings paths for government insurance beneficiaries.

Q: How much do telehealth GLP-1 programs like Hims and Ro actually cost per month?

Total monthly costs for telehealth GLP-1 programs typically range from $199 to $500+ when you add up the membership or consultation fee plus medication cost. For example, Ro charges $145/month for its Body membership plus $149-$299/month for oral Wegovy, bringing total monthly costs to $294-$444. Some platforms bundle everything into a single price, while others charge separately. Always compare total costs, not just medication prices, when evaluating platforms. Also check what clinical support is included — some platforms offer regular provider check-ins, lab monitoring, and dietitian access that you would otherwise pay for separately through your own doctor. A platform that costs $50 more per month but includes quarterly lab work and weekly dietitian check-ins may actually save you money overall.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs with potential side effects and contraindications. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results, costs, and insurance coverage vary. Pricing information in this article reflects publicly available data as of March 2026 and is subject to change.

The Bottom Line

GLP-1 medication costs in 2026 are more manageable than ever, but navigating the options takes effort. The days of a single $1,300/month price tag with no alternatives are behind us. Between manufacturer savings cards ($25/month with insurance), the oral Wegovy pill ($149/month self-pay), TrumpRx negotiated pricing ($199-$350/month), LillyDirect ($299-$449/month), and upcoming Medicare coverage ($50/month starting July 2026), there are real paths to affordability.

The key is matching the right savings strategy to your specific situation. Start with your insurance, explore manufacturer programs, and do not be afraid to ask your doctor for help navigating the prior authorization process. Access to these medications should not depend on your ability to decode a complicated pricing system, and we hope this guide makes that process a little easier.

-- The GLP-1 Daily Team